Orexin Receptors

Orexin receptor antagonists block orexin receptors 1 and 2 (OX1, OX2), which respond to orexin neuropeptides. Orexin A and orexin B were described in 1998 as hypothalamic peptides that act on these two G protein-coupled receptors. In 1999 a mutation in the orexin receptor 2 gene was found to cause canine narcolepsy. Mice lacking orexin showed a narcolepsy-like phenotype in the same year, linking the system to sleep and wakefulness. OX1 is also studied in reward, addiction and stress, and OX2 mainly in arousal. SB 334867, SB-408124 and GSK1059865 are OX1-selective antagonists, and MK-3697 targets OX2. Almorexant, TCS 1102 and nemorexant are dual antagonists that block both orexin receptors.

Items 76-76 of 76

  • MK-8133
    Cat. No.
    A62752

    MK-8133

    MK-8133 is a selective orexin-2 receptor antagonist that inhibits orexin signaling pathways. It has demonstrated efficacy in the modulation of sleep-wake cycles, making it a valuable tool for researching insomnia and other sleep disorders. This compound can be utilized in various experimental models to investigate the role of orexin in sleep regulation and potential therapeutic interventions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

Items 76-76 of 76

Added to your cart

View Cart Checkout

    Loading...